- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04465747
Egyptian Liver Library: Rebuilding the Pyramid of Liver Disease Evidence in Egypt (ELL)
July 7, 2020 updated by: Mohamed Alboraie, Al-Azhar University
A lot of publications about liver disease are available worldwide.
Egypt is one of the countries having a large number of publications in hepatology.
There are defects in reviewing this evidence and making use of it.
Addressing the areas of weakness in liver research in Egypt is challenging to researchers and clinicians.
Creating a library for liver disease evidence in Egypt can solve this problem and lead future research in hepatology in Egypt.
Study Overview
Detailed Description
Egypt is considered one of the countries with large liver disease burden in the world being endemic with bilharziasis and hepatitis C for decades.
Limitations in health care resource further augment the magnitude of the problem allowing the development of disease specific complications in absence of effective treatments over the past.
With discovery of anti-schistosomal therapy and implementation of the national program for eliminating bilharziasis; bilharzial liver disease incidence regressed markedly.
However; complications of bilharzial liver disease are still present.
The situation has been repeated with hepatitis C which is still a major health problem in Egypt regardless of the availability of highly effective interferon free antiviral regimens.
This is mainly due to the large number of infected patients (estimated to be more than 6 million) [1], re-infection and presence of complications that needs further management.
The need for addressing these major health problems in Egypt provoked a lot of research in the field of hepatology.
Egyptian and non-Egyptian researchers have published a lot of scientific reports about liver diseases in Egypt.
Since the ancient age of the pharaohs there were written evidence about liver disease in Egypt.
It was reported in the Ebres Papyrus (around 2600 BC) that hardness of the liver occurs secondary to excess alcohol ingestion [2].
This was one of the oldest documented detailed medical literatures in the history of mankind.
In the recent age there were a lot reports from Egypt about bilharziasis and other parasitic infestations as the one published by Cobbold in 1982 about injurious parasites in Egypt [3].
Further enormous amount of publications has been released afterwards.
Reviewing this evidence and creating an indexed data base for it could be of value for the national and international hepatology platforms.
I aim with other colleagues at reviewing all published evidence in the field of hepatology from Egypt up to January 2016 and classifying it by different key words to build a data base of liver disease evidence in Egypt.
This data base will be continuously updated by published data after January 1st 2016 and will be the reference for researchers from Egypt and rest of the world.
The data base will invite all authors from Egypt to provide their raw data of published articles to be available for further analyses by other researchers.
Moreover the data base work team will start a series of systematic reviews and meta analyses for the available relevant data aiming at addressing the areas of strength and areas of weakness in liver disease research in Egypt making further recommendations to the research authorities about what is missing and how it is better to be addressed in their future research calls.
This pilot research work can be reproduced elsewhere by other researchers in their own countries making use of their published data and advising their local research authorities to fill up the gaps in liver research in their own countries.
Hopefully in the near future we will have these groups working together in a network driving liver research globally.
Study Type
Observational
Enrollment (Actual)
5068
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt, 11884
- Al-Azhar Uinversity
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Published articles about liver disease up to January 2016
Description
Inclusion Criteria:
- Published articles about liver disease up to January 2016
Exclusion Criteria:
- Anything else
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Review of all published articles about liver disease in Egypt till April 2017
Time Frame: 1 year
|
Indexing articles according to types of liver disease
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identifying missing diseases in hepatology research in Egypt
Time Frame: 1 year
|
Identifying missing diseases in hepatology research in Egypt
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mohamed Alboraie, M.D., MRCP, Al-Azhay University, Cairo, Egypt
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bruggmann, P., Berg, T., Øvrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balık, İ., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S. and Hindman, S. J. (2014), Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis, 21: 5-33. doi: 10.1111/jvh.12247
- Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician. 2011 Dec 15;84(12):1353-9.
- Cobbold TS. Remarks on Injurious Parasites of Egypt in Relation to Water-Drinking. Br Med J. 1882 Sep 16;2(1133):503-4. doi: 10.1136/bmj.2.1133.503. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
January 1, 2018
Study Completion (Actual)
January 1, 2018
Study Registration Dates
First Submitted
January 30, 2016
First Submitted That Met QC Criteria
July 7, 2020
First Posted (Actual)
July 10, 2020
Study Record Updates
Last Update Posted (Actual)
July 10, 2020
Last Update Submitted That Met QC Criteria
July 7, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MB-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
Clinical Trials on Publications
-
Universidad Peruana Cayetano HerediaCompleted
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Completed